We will inform you that the patent application which was jointly filed by Repertoire Genesis Inc. (Head office: Ibaraki-shi, Osaka, Japan) and a research group of Dr. Seiji Matsumoto at Hyogo College of Medicine (Location: Nishinomiya-shi, Hyogo, Japan) has been published internationally.

・Publication No: WO/2018/168949
・International Application No: PCT/JP2018/010028
・Publication Date: 20 September, 2018

This invention provides a novel technique for predicting a responder prior to cancer immunotherapy including immune checkpoint inhibitors by diversity in terms of T cell receptor (TCR) of peripheral blood.
We are currently proceeding the verification of this biomarker for multiple cancer types and drugs. We will continue working to make precision medicine to be available for more patients as early as possible.